We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
No fiscal-year history available for this company yet.
No P/E, the company is not profitable on a trailing basis.
Locus Cell Co., Ltd. is a specialist in the biotechnology and cell therapy sector. The company primarily offers contract development and manufacturing (CDMO) services for a variety of cellular products. This includes handling diverse cell types such as adipose-derived stem cells, nerve cells, chondrocytes, and fibroblasts. Furthermore, their capabilities extend to advanced manufacturing processes like 3D bioprinting for cellular constructs. Locus Cell also provides CDMO support for cutting-edge regenerative medical products, including therapies based on CAR-T, mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs).
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 6891.TWO and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
